Alsyslife is an integrated global biopharmaceutical company engaged in discovering, developing and commercializing both first- and best-in-class therapies to address global unmet medical needs. For more than two decades, our founders and team have leveraged their deep expertise to develop our proprietary drug discovery platform to pursue particularly challenging targets. We are the only company in the world with active clinical programs targeting psoriasis, eczema, atopic dermatitis and other skin diseases. Our clinical candidates include novel PRC0028 and BA01 are AMP inhibitors, as well as candidates aimed at inhibition of TNF-alfa.